{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:36:10Z","timestamp":1790246170266,"version":"4.1.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although bortezomib is clinically approved for the treatment of mantle cell lymphoma (MCL), only limited effects of this treatment have been demonstrated. To improve survival for bortezomib-resistant patients, it is necessary to develop new therapeutic strategies. In the present study, we used biochemical and molecular methodologies to demonstrate that tissue transglutaminase (TG) activates downstream NF-\u03baB signaling pathways. The signaling axis from TG to NF-\u03baB could be a new therapeutic target to overcome bortezomib resistance in MCL. TG2 is a calcium-dependent protein cross-linking enzyme reported to be overexpressed in various cancer cells. We found that MCL cells expressed elevated levels of TG2 and that the modification of TG2 activities altered NF-\u03baB expression and downstream signaling in MCL cells. When TG2 signaling was inhibited by calcium blockers, the combination of a calcium blocker (perillyl alcohol) with bortezomib suppressed NF-\u03baB expression and improved the cytotoxicity of bortezomib in MCL cells. Our study is the first to show the expression of TG2 and the contribution of TG2 to NF-\u03baB signaling in MCL. TG2 inhibition may be used as an alternative target anti-MCL therapy, and calcium blockers may be combined with bortezomib to overcome the bortezomib resistance in MCL.<\/jats:p>","DOI":"10.1182\/blood-2011-09-377598","type":"journal-article","created":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T06:09:51Z","timestamp":1328076591000},"page":"2568-2578","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":23,"title":["Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities"],"prefix":"10.1182","volume":"119","author":[{"given":"Hyun Joo","family":"Jung","sequence":"first","affiliation":[{"name":"Centre for Stem Cell Research, Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, University of Texas Health Science Center at Houston, Houston, TX;"},{"name":"Division of Hematology-Oncology, Department of Pediatrics, Ajou University Hospital, Ajou University School of Medicine, Suwon, Korea; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Centre for Stem Cell Research, Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, University of Texas Health Science Center at Houston, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Fayad","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Romaguera","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry W.","family":"Kwak","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nami","family":"McCarty","sequence":"additional","affiliation":[{"name":"Centre for Stem Cell Research, Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, University of Texas Health Science Center at Houston, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2019111808154975600_B1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111808154975600_B2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.critrevonc.2010.09.003","article-title":"Mantle cell lymphoma: The promise of new treatment options.","volume":"80","author":"Goy","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2019111808154975600_B3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2141.2010.08315.x","article-title":"Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.","volume":"151","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111808154975600_B4","first-page":"115","article-title":"Mantle-cell lymphoma.","volume":"36","author":"Campo","year":"1999","journal-title":"Semin Hematol"},{"issue":"879","key":"2019111808154975600_B5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/pgmj.75.879.2","article-title":"Management of non-Hodgkin's lymphomas.","volume":"75","author":"Mounter","year":"1999","journal-title":"Postgrad Med J"},{"issue":"1","key":"2019111808154975600_B6","first-page":"11","article-title":"Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives.","volume":"91","author":"Salaverria","year":"2006","journal-title":"Haematologica"},{"issue":"11","key":"2019111808154975600_B7","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3324\/haematol.2009.013359","article-title":"Mantle cell lymphoma.","volume":"94","author":"Pileri","year":"2009","journal-title":"Haematologica"},{"issue":"18 Pt 1","key":"2019111808154975600_B8","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1158\/1078-0432.CCR-07-0871","article-title":"Bortezomib for the treatment of mantle cell lymphoma.","volume":"13","author":"Kane","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2019111808154975600_B9","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","article-title":"Proteasome inhibition as a novel therapeutic target in human cancer.","volume":"23","author":"Rajkumar","year":"2005","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111808154975600_B10","first-page":"6316","article-title":"The proteasome as a target for cancer therapy.","volume":"9","author":"Voorhees","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2019111808154975600_B11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: a suitable antineoplastic target.","volume":"4","author":"Adams","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2019111808154975600_B12","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","article-title":"Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis.","volume":"171","author":"Pham","year":"2003","journal-title":"J Immunol"},{"key":"2019111808154975600_B13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1476-4598-7-40","article-title":"Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.","volume":"7","author":"Yang","year":"2008","journal-title":"Mol Cancer"},{"issue":"4","key":"2019111808154975600_B14","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.","volume":"23","author":"O'Connor","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111808154975600_B15","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111808154975600_B16","doi-asserted-by":"crossref","first-page":"9695","DOI":"10.1128\/MCB.24.22.9695-9704.2004","article-title":"Proteasome inhibitor PS341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.","volume":"24","author":"Fribley","year":"2004","journal-title":"Mol Cell Biol"},{"issue":"12","key":"2019111808154975600_B17","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"issue":"15","key":"2019111808154975600_B18","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1158\/1078-0432.CCR-10-3367","article-title":"Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma.","volume":"17","author":"Weniger","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2019111808154975600_B19","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/leu.2010.137","article-title":"Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.","volume":"24","author":"Ri","year":"2010","journal-title":"Leukemia"},{"issue":"5","key":"2019111808154975600_B20","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","article-title":"Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.","volume":"114","author":"Hideshima","year":"2009","journal-title":"Blood"},{"issue":"31","key":"2019111808154975600_B21","doi-asserted-by":"crossref","first-page":"22118","DOI":"10.1074\/jbc.M601350200","article-title":"Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants.","volume":"281","author":"Dolcet","year":"2006","journal-title":"J Biol Chem"},{"issue":"3","key":"2019111808154975600_B22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.scr.2010.07.003","article-title":"Prospective isolation of clonogenic mantle cell lymphoma-initiating cells.","volume":"5","author":"Chen","year":"2010","journal-title":"Stem Cell Res"},{"issue":"6","key":"2019111808154975600_B23","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3109\/10428194.2011.562570","article-title":"Stem-like tumor cells confer drug resistant properties to mantle cell lymphoma.","volume":"52","author":"Jung","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019111808154975600_B24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.exphem.2011.10.004","article-title":"Bortezomib-resistant nuclear factor kappa B expression in stem like cells in mantle cell lymphoma (MCL).","volume":"40","author":"Jung","year":"2012","journal-title":"Exp Hematol"},{"issue":"1","key":"2019111808154975600_B25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CAD.0b013e32832a68ad","article-title":"Perillyl alcohol and methyl jasmonate sensitize cancer cells to cisplatin.","volume":"21","author":"Yeruva","year":"2010","journal-title":"Anticancer Drugs"},{"issue":"18","key":"2019111808154975600_B26","doi-asserted-by":"crossref","first-page":"8558","DOI":"10.1158\/0008-5472.CAN-04-4072","article-title":"Perillyl alcohol inhibits a calcium-dependent constitutive nuclear factor-kappaB pathway.","volume":"65","author":"Berchtold","year":"2005","journal-title":"Cancer Res"},{"issue":"7","key":"2019111808154975600_B27","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1593\/neo.10228","article-title":"Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells.","volume":"12","author":"Meister","year":"2010","journal-title":"Neoplasia"},{"issue":"pt 2","key":"2019111808154975600_B28","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1042\/bj20021234","article-title":"Transglutaminases: nature's biological glues.","volume":"368","author":"Griffin","year":"2002","journal-title":"Biochem J"},{"issue":"23","key":"2019111808154975600_B29","doi-asserted-by":"crossref","first-page":"20127","DOI":"10.1074\/jbc.C200147200","article-title":"Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb.","volume":"277","author":"Boehm","year":"2002","journal-title":"J Biol Chem"},{"issue":"23","key":"2019111808154975600_B30","doi-asserted-by":"crossref","first-page":"8068","DOI":"10.1158\/1078-0432.CCR-04-1107","article-title":"Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer.","volume":"10","author":"Mehta","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"Pt 16","key":"2019111808154975600_B31","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1242\/jcs.114.16.2989","article-title":"Cell-surface transglutaminase promotes fibronectin assembly via interaction with the gelatin-binding domain of fibronectin: a role in TGFbeta-dependent matrix deposition.","volume":"114","author":"Akimov","year":"2001","journal-title":"J Cell Sci"},{"issue":"2","key":"2019111808154975600_B32","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1128\/MCB.26.2.569-579.2006","article-title":"Tissue transglutaminase serves as an inhibitor of apoptosis by cross-linking caspase 3 in thapsigargin-treated cells.","volume":"26","author":"Yamaguchi","year":"2006","journal-title":"Mol Cell Biol"},{"issue":"22","key":"2019111808154975600_B33","doi-asserted-by":"crossref","first-page":"10936","DOI":"10.1158\/0008-5472.CAN-06-1521","article-title":"Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation.","volume":"66","author":"Kim","year":"2006","journal-title":"Cancer Res"},{"issue":"3","key":"2019111808154975600_B34","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ijc.2910580316","article-title":"High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells.","volume":"58","author":"Mehta","year":"1994","journal-title":"Int J Cancer"},{"issue":"17","key":"2019111808154975600_B35","doi-asserted-by":"crossref","first-page":"8788","DOI":"10.1158\/0008-5472.CAN-06-1457","article-title":"Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway.","volume":"66","author":"Mann","year":"2006","journal-title":"Cancer Res"},{"issue":"9","key":"2019111808154975600_B36","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1158\/1535-7163.MCT-04-0328","article-title":"Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas.","volume":"4","author":"Yuan","year":"2005","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"2019111808154975600_B37","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2174\/156800907781662275","article-title":"Transglutaminase-mediated activation of nuclear transcription factor-kappaB in cancer cells: a new therapeutic opportunity.","volume":"7","author":"Verma","year":"2007","journal-title":"Curr Cancer Drug Targets"},{"issue":"51","key":"2019111808154975600_B38","doi-asserted-by":"crossref","first-page":"53725","DOI":"10.1074\/jbc.M407627200","article-title":"Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia.","volume":"279","author":"Lee","year":"2004","journal-title":"J Biol Chem"},{"key":"2019111808154975600_B39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"issue":"1","key":"2019111808154975600_B40","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1432-1033.1981.tb06218.x","article-title":"Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors.","volume":"115","author":"Chou","year":"1981","journal-title":"Eur J Biochem"},{"issue":"2","key":"2019111808154975600_B41","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0022-5193(76)90169-7","article-title":"Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands.","volume":"59","author":"Chou","year":"1976","journal-title":"J Theor Biol"},{"issue":"3","key":"2019111808154975600_B42","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0092-8674(00)80929-0","article-title":"The proteasome: paradigm of a self-compartmentalizing protease.","volume":"92","author":"Baumeister","year":"1998","journal-title":"Cell"},{"key":"2019111808154975600_B43","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1146\/annurev.bi.65.070196.004101","article-title":"Structure and functions of the 20S and 26S proteasomes.","volume":"65","author":"Coux","year":"1996","journal-title":"Annu Rev Biochem"},{"key":"2019111808154975600_B44","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.2741\/2030","article-title":"Transglutaminase 2 in inflammation.","volume":"11","author":"Kim","year":"2006","journal-title":"Front Biosci"},{"issue":"2","key":"2019111808154975600_B45","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00726-007-0517-0","article-title":"Tissue transglutaminase and the stress response.","volume":"33","author":"Ientile","year":"2007","journal-title":"Amino Acids"},{"issue":"2","key":"2019111808154975600_B46","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1158\/1940-6207.CAPR-09-0183","article-title":"A phase 2a study of topical perillyl alcohol cream for chemoprevention of skin cancer.","volume":"3","author":"Stratton","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"issue":"2","key":"2019111808154975600_B47","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00432-010-0873-0","article-title":"Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma.","volume":"137","author":"da Fonseca","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"2019111808154975600_B48","first-page":"321","article-title":"Characterization of a transglutaminase expressed in human pancreatic adenocarcinoma cells.","volume":"61","author":"Els\u00e4sser","year":"1993","journal-title":"Eur J Cell Biol"},{"issue":"4-5","key":"2019111808154975600_B49","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.drup.2007.06.002","article-title":"Tissue transglutaminase-mediated chemoresistance in cancer cells.","volume":"10","author":"Verma","year":"2007","journal-title":"Drug Resist Updat"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/11\/2568\/1350780\/zh801112002568.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/11\/2568\/1350780\/zh801112002568.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T19:47:47Z","timestamp":1713469667000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/11\/2568\/29634\/Calcium-blockers-decrease-the-bortezomib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,15]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,3,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-09-377598","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,15]]}}}